Stockreport

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Inc. - Common Shares  (PMN) 
PDF Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer’s Disease PRECISE-AD Six Mo [Read more]